Bruker

Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) Life Science, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI Life Science segment includes enabling life science tools based on magnetic resonance technology. The BSI Nano segment offers x-ray instruments that use electromagnetic radiation with wavelengths to determine the characteristics of matter and the three-dimensional (3D) structure of molecules. The BEST segment consists of conducting materials, primarily metallic low temperature superconductors, for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research, and other applications. The company was founded by Gunther Laukien in 1960 and is headquartered in Billerica, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bruker reports robust 2022 performance, eyes growth amid challenges

Bruker's strong financial performance in 2022, driven by organic revenue growth and strategic investments, positions the company for continued success.
While facing supply chain challenges and geopolitical risks, Bruker remains optimistic about growth opportunities in proteomics and spatial biology.
Confidence in 2023 outlook is supported by strong bookings, backlog visibility, and expectations of solid organic growth in key markets.

Bruker reports strong Q1 earnings, eyes spatial biology markets

Bruker's Q1 2023 performance showcased robust revenue growth and margin improvement, with strong demand across key segments and regions.
While facing challenges like margin declines and supply chain constraints, the company is well-positioned to capitalize on opportunities in spatial biology and proteomics markets.
By focusing on innovation, capacity investments, and addressing backlog delays, Bruker aims to sustain growth momentum and meet future demand expectations.
Overall, Bruker's strategic initiatives and market positioning indicate a positive outlook for continued growth and market leadership in the analytical instruments industry.

Bruker reports strong Q2 earnings, eyes global growth opportunities

Bruker's Q2 2023 performance reflects strong revenue and EPS growth, driven by demand across key segments and regions. The company's focus on innovation and global expansion positions it well for future growth.
While facing challenges such as high lead times and supply chain issues, Bruker is proactively managing costs and investing in capacity to meet demand. Opportunities for organic growth and profitability through strategic investments and pricing trends are on the horizon.
Overall, Bruker's Q2 2023 earnings call highlights a resilient performance, strategic strengths in R&D and global presence, challenges in capacity and logistics, and opportunities for sustained growth and profitability.

Bruker reports strong Q3 earnings and eyes sustainable growth

Bruker's Q3 2023 performance reflects robust revenue and earnings growth, supported by strong organic growth and strategic acquisitions.
While facing challenges in biopharma investments and China trends, Bruker's strengths lie in its elevated backlog and growth opportunities in green tech and academic funding.
The company's focus on high-end Life Science tools in China and long-term growth prospects position it well for sustained success.
Overall, Bruker's performance in Q3 2023 showcases resilience and strategic positioning for future growth.

Bruker excels in Q4 2023, eyes accelerated growth and acquisitions

Bruker's strong Q4 2023 performance showcased robust revenue and EPS growth, though challenges like margin pressure and geopolitical risks persist. With a focus on strategic acquisitions and market opportunities, Bruker aims for continued growth and innovation.

Bruker boosts revenue guidance after Q1 growth, faces margin challenges

Bruker's Q1 2024 performance showed growth despite margin challenges, with increased revenue guidance for the year.
Strong geographic revenue growth in the Americas and Europe contrasted with a decline in Asia Pacific.
Strategic acquisitions and focus on organic growth present opportunities for Bruker in 2024.
Challenges include margin compression, dilution from integration, and lower organic growth due to order distortions.

Bruker reports robust Q2 earnings, eyes growth in key sectors

Bruker's strong Q2 performance and strategic acquisitions are driving growth in key areas like spatial biology and molecular diagnostics.
While facing margin challenges due to recent acquisitions, the company remains confident in achieving operational excellence and margin expansion.
Maintaining mid-single-digit organic revenue growth and focusing on operational efficiency position Bruker for continued success in the market.
The company's outlook remains positive with opportunities for growth through acquisitions and market demand for its innovative solutions.

Bruker reports strong Q3 earnings, eyes margin expansion in 2025

Bruker's Q3 '24 performance was strong, with revenue growth and margin improvements.
Challenges include weaker-than-expected demand in biopharma and China markets.
Anticipated opportunities lie in margin expansion and innovative solutions in 2025.
Focus on driving improvements in acquired businesses to drive growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI BioSpin segment includes life science tools based on magnetic resonance technology. The BSI CALID segment focuses on life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions based on infrared and Raman molecular spectroscopy technologies and radiological and nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The BSI Nano segment offers advanced x-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments, analytical tools for electron microscopes and x-ray metrology, defect-detection equipment for semiconductor process control, handheld, portable, and mobile x-ray fluorescence spectrometry instruments, spark optical emission spectroscopy systems, and chip cytometry products and services for targeted spatial proteomics, multi-omics services, and products and services for spatial genomics research. The BEST segment is involved in superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare, and big science research. The company was founded by Emil Bruker and Günther Laukien in 1960 and is headquartered in Billerica, MA.

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for its first quarter ended March 31, 2022. First Quarter 2022 Financial Results Bruker's revenues for the first quarter of 2022 were $595.0 million, an increase of 7.3% compared to $554.7 million in the first quarter of 2021. In the first quarter of 2022, revenues increased 10.5% organically year-over-year. Growth from acquisitions was 1.0%, while foreign currency transactions had a negative

Bruker Reports First Quarter Financial Results

ORLANDO, Fla.--(BUSINESS WIRE)---- $BRKR #BRKR--At the Experimental Nuclear Magnetic Resonance Conference (ENC 2022), Bruker demonstrates a novel and remarkably compact 1.0 GHz NMR magnet, operating at 4.2 Kelvin, for structural biology applications in single-story standard laboratories. Bruker also offers innovations and services for reducing liquid helium consumption. A major innovation and technology introduction from Bruker is the recent successful factory energization and protein NMR testing of a unique s

Bruker Demonstrates Novel and Unique Compact 1.0 GHz NMR Magnet

LISBON, Portugal--(BUSINESS WIRE)---- $BRKR #BRKR--At the 32nd European Congress of Clinical Microbiology & Infectious Diseases (www.eccmid.org), Bruker Corporation (Nasdaq: BRKR) announces further advances in its market-leading MALDI Biotyper® (MBT) platform, and launches new multiplex PCR infectious disease assays that are based on its proprietary LiquidArray® technology. Bruker further expands its mycobacteria portfolio with the FluoroType® Mycobacteria PCR assay, launched on the high-precision FluoroCy

Bruker Launches Unique LiquidArray® Multiplex PCR Assays

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report first quarter 2022 financial results before market opening on Wednesday, May 4, 2022. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q1 2022 Earnings Webcast” hyperlink in the “Events & Presentations” section. A slide presenta

Bruker Announces Date and Time of First Quarter 2022 Earnings Release and Webcast

Bruker's (BRKR) latest innovation for cancer research is likely to strengthen the company's opportunities in proteomics and spatial biology.

Bruker (BRKR) Unveils New Imaging Tools for Cancer Research

NEW ORLEANS--(BUSINESS WIRE)---- $BRKR #BRKR--At the AACR Annual Meeting 2022, Bruker Corporation (Nasdaq: BRKR) launched and exhibited unique and novel capabilities for spatial multiomics, single-cell proteomics, and cell-line, tissue and plasma proteomics cancer research. Following up on Bruker's recent strategic investment in AmberGen Inc., Bruker is announcing a partnership for the application of Ambergen Miralys™ peptide-code antibody kits for the Bruker timsTOF flex novel MALDI HiPLEX-IHC workflow for ta

Bruker Announces Key Innovations for Multiplexed Spatial Proteomics and Unbiased Multiomic Imaging for Cancer Research

Bruker's (BRKR) acquisition of IonSense will reach the DART ionization technology to a wider customer base.

Bruker's (BRKR) Buyout to Expand Mass Spectrometry Prospects

SAUGUS, Mass.--(BUSINESS WIRE)--IonSense Inc., the innovator of ambient DART™ (Direct Analysis in Real Time) ionization technology, announces that it has been acquired by Bruker Corporation (Nasdaq: BRKR). The deal provides IonSense with the financial investments to ramp up development of the DART ionization source technology and increase efforts in developing applications in the applied markets, including food analysis and forensics. “This merger will help us to accelerate development of DART

IonSense, a Leader In DART™ Mass Spectroscopy, Announces Acquisition by Bruker to Accelerate DART-MS Methods and Applications Development

Bruker's (BRKR) recent buyout strengthens the company as a key software and solutions provider for small molecule, biologics and new drug modalities pharma companies.

Bruker (BRKR) to Support Biopharma Industries With New Buyout

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Optimal Industrial Automation and Technologies, a leader in pharma and biopharma process analytical technology (PAT), pharma manufacturing automation and Quality Assurance (QA) software and systems integration, based in the United Kingdom. The Optimal biopharma tools acquisition strengthens Bruker as a key software and solutions provider for small molecule, biologics and new drug modalities p

Bruker Acquires Optimal Companies for Pharma PAT Software and Biopharma Manufacturing Automation Expertise and Technologies

Bruker's (BRKR) Nano Group microelectronics and semiconductor metrology tools continue to perform well on ongoing strength in bookings and backlog.

Here's Why You Should Add Bruker (BRKR) Stock to Your Kitty

LEIPZIG, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--At the Proteomic Forum | EuPA 2022, Bruker Corporation (Nasdaq: BRKR) announced expanded capabilities for deeper proteomic and epiproteomic coverage, including enhanced phosphopeptide analysis using the innovative TIMScore algorithm, which is now a part of the new PaSER 2022 GPU-based platform. The novel TIMScore algorithm takes advantage of machine learning (ML) to predict CCS values of tryptic and phosphorylated peptides. Experimentally measured CCS values a

Bruker Expands dia-PASEF® on the timsTOF 4D Proteomics and Epiproteomics Platform to Identify up to 13,000 Protein Groups with 1% FDR

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has appointed Philip Ma, Ph.D. to serve on its board, effective as of April 1, 2022. Dr. Ma is Chief Executive Officer, founder, and a director of PrognomiQ, a privately held healthcare company that is developing next-generation, transformative multiomics products to enable early cancer detection and cancer treatment selection and monitoring assays. Before PrognomiQ, Dr. Ma was Chief

Bruker Appoints Philip Ma to its Board of Directors

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announces new capabilities for its benchtop Fourier transform (FT) nuclear magnetic resonance (NMR) spectrometer, the Fourier 80, which does not require special lab infrastructure or cryogens, and offers excellent 1H sensitivity of 200:1 for gradient spectroscopy proton probes. A new adjustable temperature option increases experimental flexibility, while new solutions for pharma and food analysis provide improved synthes

Announcing New Fourier 80 Benchtop FT-NMR Capabilities for Pharmaceutical and Food Analysis Markets

The consensus price target hints at a 33.5% upside potential for Bruker (BRKR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Bruker (BRKR) Have the Potential to Rally 33% as Wall Street Analysts Expect?

Bruker's (BRKR) acquired company, Canopy Biosciences, introduced its next generation of ChipCytometry instrumentation for spatial biology.

Bruker (BRKR) to Improve Spatial Biology With New Launch

ST. LOUIS--(BUSINESS WIRE)---- $BRKR #BRKR--Canopy Biosciences, a Bruker Company, today announced the commercial launch of the CellScapeTM system, the next generation in ChipCytometryTM instrumentation, advancing the cutting-edge for quantitative in situ spatial phenotyping. ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumor microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease. The new

Canopy Biosciences Launches Next-Generation ChipCytometry™ Instrument for Spatial Biology with Sub-Cellular Resolution

The maxis II and timsTOF Pro 2 mass spectrometers from Bruker (BRKR) will be marketed with Newomics's MnESI product line.

Bruker (BRKR), Newomics to Co-Market Joint MnESI-MS Platform

BERKELEY, Calif.--(BUSINESS WIRE)--Newomics Inc., a biotechnology company commercializing mass spectrometry solutions for molecular detection, and Bruker Corporation, with differentiated high-value life science research and diagnostics solutions, today announced collaborations on a novel LC-MS platform for drug discovery in the Pharma/Biopharma industry as well as research institutions. The two companies agreed on co-marketing Newomics's Microflow-nanospray Electrospray Ionization (MnESI) produ

Newomics and Bruker Announce Collaborations on High-throughput Bioanalysis

Investors are optimistic about Bruker's (BRKR) better-than-expected revenues and robust segmental performance.

Here's Why You Should Invest In Bruker (BRKR) Stock Now

CHARLESTON, S.C.--(BUSINESS WIRE)---- $BRKR #BRKR--At US HUPO, Bruker Corporation (Nasdaq: BRKR) announced its TIMS DIA-NN software for the high-throughput, deep and unbiased 4D proteomics workflow. It now features the novel TIMScore algorithm which takes advantage of machine learning (ML) to predict CCS values of tryptic and phosphorylated peptides. With TIMScore, the measured CCS values are referenced against the predicted CCS values within the search space to call the most probable assignment, even when trad

Bruker Releases CCS-Enabled TIMScore™ and TIMS DIA-NN 4D Proteomics Software

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in Cowen's 42nd Annual Health Care Conference which is taking place virtually on March 7 - 9, 2022. Gerald Herman, Executive Vice President & CFO will present on behalf of the Company on Monday, March 7th, 2022 at 2:50 PM Eastern Standard Time. A live audiovisual webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.

Bruker Corporation to Present at Cowen's 42nd Annual Health Care Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 31.4% in Bruker (BRKR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 31% Upside in Bruker (BRKR): Can the Stock Really Move This High?

Mettler-Toledo

The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD) and Bruker (BRKR) are gaining from strong life science, pharmaceutical and academic end-market demand as well as rising healthcare spending.

2 Stocks to Buy on Rising Demand for Scientific Instruments

Robust performance by the BSI and BEST segments drove Bruker's (BRKR) fourth-quarter top line.

News for Bruker Stock (BRKR)